TScan Therapeutics, Inc. (TCRX)
NASDAQ: TCRX · Real-Time Price · USD
1.260
-0.050 (-3.82%)
At close: Apr 28, 2026, 4:00 PM EDT
1.270
+0.010 (0.79%)
After-hours: Apr 28, 2026, 4:10 PM EDT
TScan Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for TScan Therapeutics stock have an average target of 7.00, with a low estimate of 5.00 and a high estimate of 10. The average target predicts an increase of 455.56% from the current stock price of 1.26.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 5, 2026.
Analyst Ratings
The average analyst rating for TScan Therapeutics stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Buy | 2 | 2 | 2 | 2 | 3 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 8 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Maintains $4 → $5 | Buy | Maintains | $4 → $5 | +296.83% | Mar 5, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $10 → $7 | Strong Buy | Maintains | $10 → $7 | +455.56% | Nov 13, 2025 |
| BTIG | BTIG | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Nov 4, 2025 |
| Needham | Needham | Strong Buy Maintains $9 → $6 | Strong Buy | Maintains | $9 → $6 | +376.19% | Nov 4, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $15 → $10 | Strong Buy | Maintains | $15 → $10 | +693.65% | May 7, 2025 |
Financial Forecast
Revenue This Year
8.64M
from 10.33M
Decreased by -16.34%
Revenue Next Year
10.35M
from 8.64M
Increased by 19.81%
EPS This Year
-0.78
from -1.00
EPS Next Year
-0.89
from -0.78
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 11.4M | 12.0M | ||||||
| Avg | 8.6M | 10.3M | ||||||
| Low | 2.5M | 8.8M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 10.2% | 38.4% | ||||||
| Avg | -16.3% | 19.8% | ||||||
| Low | -76.3% | 2.1% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.71 | -0.70 | ||||||
| Avg | -0.78 | -0.89 | ||||||
| Low | -0.87 | -1.12 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.